Pembrolizumab Experience in a Patient with Progressive Multifocal Leukoencephalopathy Following Multiple Myeloma Treatment: A Case Report and Literature Review.
증례보고
1/5 보강
[INTRODUCTION] Progressive multifocal leukoencephalopathy (PML) is a progressive demyelinating infection of the central nervous system.
APA
Yıldız MS, Maharramov E, et al. (2026). Pembrolizumab Experience in a Patient with Progressive Multifocal Leukoencephalopathy Following Multiple Myeloma Treatment: A Case Report and Literature Review.. Noro psikiyatri arsivi, 63, 350-353. https://doi.org/10.29399/npa.29259
MLA
Yıldız MS, et al.. "Pembrolizumab Experience in a Patient with Progressive Multifocal Leukoencephalopathy Following Multiple Myeloma Treatment: A Case Report and Literature Review.." Noro psikiyatri arsivi, vol. 63, 2026, pp. 350-353.
PMID
41969960 ↗
Abstract 한글 요약
[INTRODUCTION] Progressive multifocal leukoencephalopathy (PML) is a progressive demyelinating infection of the central nervous system. PML arises in immunosuppressive conditions or circumstances necessitating immunosuppressive treatment, such as malignancies. Recently, data have been published regarding the use of different immune checkpoint inhibitors (ICIs) for the treatment of PML. However, the extent to which ICIs impact and improve PML in individual patients remains uncertain.
[CASE] A 68-year-old female patient, diagnosed with multiple myeloma in 2012 and with a history of using various chemotherapeutic agents, presented with dizziness, gait disturbances, and speech difficulties. The patient was diagnosed with PML and started on pembrolizumab treatment. This treatment led to improvements in both clinical symptoms and imaging findings.
[CONCLUSION] Regardless of the underlying cause in PML, the use of ICIs can improve the clinical course of the disease and prolong the patient's lifespan.
[CASE] A 68-year-old female patient, diagnosed with multiple myeloma in 2012 and with a history of using various chemotherapeutic agents, presented with dizziness, gait disturbances, and speech difficulties. The patient was diagnosed with PML and started on pembrolizumab treatment. This treatment led to improvements in both clinical symptoms and imaging findings.
[CONCLUSION] Regardless of the underlying cause in PML, the use of ICIs can improve the clinical course of the disease and prolong the patient's lifespan.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Assessment tools for peripheral neuropathy in multiple myeloma.
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
- Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma.
- Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database.
- Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison.
- Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.